Therapeutic effects of systemic transplantation of cultured autologous mesenchymal stem cells derived from bone marrow in patients with resistant pulmonary tuberculosis
- Authors: Vasiljeva I.A.1, Konoplyannikov A.G.2, Erokhin V.V.1, Tsyb A.F.2, Bagdasaryan T.R.1, Danilenko A.A.2, Lepekhina L.A.2, Kalsina S.S.2, Semenkova I.V.2, Agaeva E.V.2
-
Affiliations:
- Central Tuberculosis Research Institute, RAMS
- Medical Radiological Research Center, RAMS
- Issue: Vol 2, No 1 (2007)
- Pages: 77-80
- Section: Clinical experience
- URL: https://genescells.ru/2313-1829/article/view/183663
- ID: 183663
Cite item
Abstract
Systemic transplantation of mesenchymal stem cells (MSC) is known to promote reparative process in a number of tissue damage as well as lung tissue one. It provided the basis for our study which was aimed to the effect of systemic transplantation of autologous MSC (intravenous transfusion) in complex therapy of patients with resistant pulmonary tuberculosis. Started three years ago, 27 tuberculous patients are being under our observation now; 15 patients were classified as having multidrug resistance, 12 cases - as being X-drug resistant. Bacterioexcretion and substantial pulmonary cavitation were observed in every patient, most of them (n=17) having chronic tuberculosis of 13 months to 5 years duration, the rest 10 patients diagnosed 6 to 12 months before including them to the study. All these patients had previously been undertreated or unsuccessfully treated, with one patient having one lung removed. Undergone systemic transplantation of 150-200 million of cultured MSCs derived from autlogous bone marrow the patients continued conservative therapy started before. 16 patients have been under observation for 1.5 -2 years and longer after transplantation, the rest 11 patients observed not less than 6 months. MSC- introduction gave positive clinical effects in all 27 cases: somatic status improvement, dyspnoea reduction, relieving of weakness and indisposition, putting on weight (24 cases). 3-4 months after transplantation bacterioexcretion was noticed to stop in 20 patients, in 11 patients long-termed cavities healed later. At present 9 of 16 patients who had MSC transplantation 1.5-2 years ago can be stated to have stable remission of tuberculosis, 6 patients of this group demonstrate significant positive bacteriological and morphological dynamics. Only in one of 16 cases MSC transplantation resulted in short clinical improvement. Thus, MSC transplantation as a part of antitubercular therapy can be perspective in enhancing treatment of patients with drug-resistant tuberculosis.
Full Text

About the authors
I. A. Vasiljeva
Central Tuberculosis Research Institute, RAMS
Author for correspondence.
Email: konopl@mrrc.obninsk.ru
Russian Federation, Moscow
A. G. Konoplyannikov
Medical Radiological Research Center, RAMS
Email: konopl@mrrc.obninsk.ru
Russian Federation, Obninsk
V. V. Erokhin
Central Tuberculosis Research Institute, RAMS
Email: konopl@mrrc.obninsk.ru
Russian Federation, Moscow
A. F. Tsyb
Medical Radiological Research Center, RAMS
Email: konopl@mrrc.obninsk.ru
Russian Federation, Obninsk
T. R. Bagdasaryan
Central Tuberculosis Research Institute, RAMS
Email: konopl@mrrc.obninsk.ru
Russian Federation, Moscow
A. A. Danilenko
Medical Radiological Research Center, RAMS
Email: konopl@mrrc.obninsk.ru
Russian Federation, Obninsk
L. A. Lepekhina
Medical Radiological Research Center, RAMS
Email: konopl@mrrc.obninsk.ru
Russian Federation, Obninsk
S. Sh. Kalsina
Medical Radiological Research Center, RAMS
Email: konopl@mrrc.obninsk.ru
Russian Federation, Obninsk
I. V. Semenkova
Medical Radiological Research Center, RAMS
Email: konopl@mrrc.obninsk.ru
Russian Federation, Obninsk
E. V. Agaeva
Medical Radiological Research Center, RAMS
Email: konopl@mrrc.obninsk.ru
Russian Federation, Obninsk
References
- Battler A., Leor J. Stem cell and gene-based therapy. Frontiers in regenerative medicine. L., Springer-Verlag, 2006.
- Gnecchi M., HeH., Nicolas Noiseux N. et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. The FASEB J. 2006; 20: 661 -9.
- Цыб А.Ф., Коноплянников А. Г, Колесникова А.И., и др. Получение и использование в медицине клеточных культур из мезенхимальных стволовых клеток костного мозга человека. Вестник Российской Академии медицинских наук. 2004; 59(9): 71-6.
- Brocker V., Florian Langer F., Tariq G. et al. Fibroblasts of recipient origin contribute to bronchiolitis obliterans in human lung transplants. American Journal of Respiratory and Critical Care Medicine. 2006;173(11): 1276-82.
- Weiss D.J, Berberich M.A, Borok Z. et al. Adult stem cells, lung biology, and lung disease. NHLBI/Cystic Fibrosis Foundation Workshop. Proc Am. Thorac Soc. 2006; 3(3): 193-207.
- Kotton D. N., Fabian A. J., Mulligan R. C. Failure of bone marrow to reconstitute lung epithelium. Am. J. Respir. Cell Mol. Biol. 2005; 33(4): 328-34.
- MacPherson H., Keir P., S. Webb S. et al. Bone marrow-derived SP cells can contribute to the respiratory tract of mice in vivo. J. Cell Sci. 2005; 118(Pt 11): 2441-50.
- Ерохин В.В., Цыб А.Ф., Чуканов В.И. и др. Клеточные технологии в терапии хронического мультирезистентного туберкулеза легких. Проблемы туберкулеза и болезней легких. 2006; (8): 3-5.
- Ryan J.M., Barry F.P., Murphy J.M., Mahon B.P. Mesenchymal stem cells avoid allogeneic rejection. J. Inflammation, 2005; 2(8): 1-11.
- Thum T., Bauersachs J., Barry F.P. et al. The dying stem cell hypothesis. J. Amer. Coll. of Cardiology. 2005; 46(10): 1799-802.
Supplementary files
